Ketanserin
| Clinical data | |
|---|---|
| Trade names | Sufrexal, Serefrex |
| Other names | R-41468; R41468; R-41,468; KJK-945; R-49945; R49945 |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Protein binding | 95% (mainly albumin |
| Metabolism | Extensive |
| Metabolites | • Ketanserin-ol |
| Elimination half-life | 10–29 hours |
| Excretion | Urine; 2% unchanged |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.070.598 |
| Chemical and physical data | |
| Formula | C22H22FN3O3 |
| Molar mass | 395.434 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ketanserin, sold under the brand name Sufrexal, is an antihypertensive agent which is used to treat arterial hypertension and vasospastic disorders. It is also used in scientific research as an antiserotonergic agent in the study of the serotonin system; specifically, the 5-HT2 receptor family. The drug is taken by mouth.
Side effects of ketanserin include dizziness, tiredness, edema, dry mouth, weight gain, and QT interval prolongation. Ketanserin acts as a selective antagonist of the serotonin 5-HT2A, α1-adrenergic, and histamine H1 receptors. It also shows lower affinity for various other targets.
Ketanserin was discovered at Janssen Pharmaceutica in 1980. It was the first serotonin 5-HT2A receptor antagonist to be discovered that showed selectivity over other serotonin receptors. The drug is not available in the United States and is mostly no longer marketed throughout the rest of the world.